Discontinuation report MODULON
Report ID | 73450 |
Drug Identification Number | 00803499 |
Brand name | MODULON |
Common or Proper name | Modulon |
Company Name | APTALIS PHARMA CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | TRIMEBUTINE MALEATE |
Strength(s) | 200MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100's |
ATC code | A03AA |
ATC description | DRUGS FOR FUNCTIONAL BOWEL DISORDERS |
Reason for discontinuation | Other (Please describe in comments) |
Anticipated discontinuation date | 2019-01-31 |
Actual discontinuation date | 2019-01-31 |
Remaining supply date | 2019-01-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | Stock run-out date = Jan 31st |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2019-02-01 | English | Compare |
v2 | 2019-01-24 | French | Compare |
v1 | 2019-01-24 | English | Compare |
Showing 1 to 3 of 3